High-Investment Medications – Proceedings from the AMCP Partnership Forum
As novel therapies to address important medical needs are approved, the high costs for these medications — especially cell and gene therapies — can raise sustainability and affordability concerns for employers, payers, and patients. To explore alternative payment models, financial tools, and policy initiatives to improve the predictability, affordability, and accessibility of high-investment treatments and ensure patients get the medications they need at a cost they can afford, AMCP held a multi-stakeholder Partnership Forum in Arlington, VA, April 26 and 27, 2022. Together the group:
1. Identified stakeholder challenges associated with high-investment medications.
2. Explored the challenges and opportunities related to financial tools to address predictability, affordability, and accessibility for high-investment medications, and;
3. Determined the challenges and opportunities of potential policy solutions to improve the predictability, affordability, and accessibility of high-investment treatments.
Moderator:
Jennifer S. Graff, PharmD
Sr. Director, Professional Affairs, AMCP
Speakers:
![Brent Eberie](/sites/default/files/styles/default_embedded_media_480_/public/images/118857290_brent_picture%201.png.webp?itok=WgOVfnT5)
Brent Eberle, RPh, MBA
Sr. Vice President, Chief Pharmacy Officer
Navitus Health Solutions
![Anne Jackson](/sites/default/files/styles/default_embedded_media_480_/public/images/118857290_jackson_0.png.webp?itok=XvI1H0BZ)
Anne Jackson, FSA, MAAA
Principal and Consulting Actuary
Milliman, Inc
![Erin Lopata](/sites/default/files/styles/default_embedded_media_480_/public/images/118857290_erin_lopata_sq_01_2.jpg.webp?itok=jvhkL034)
Erin Lopata, PharmD, MPH
Vice President, Access Experience Team
PRECISIONvalue